Molecular Targeted Therapy

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Also Known As:

Networked: 2152 relevant articles (209 outcomes, 215 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Ramaiya, Nikhil H: 19 articles (07/2022 - 04/2012)
2.	Jagannathan, Jyothi P: 19 articles (01/2017 - 04/2012)
3.	Krajewski, Katherine M: 15 articles (01/2017 - 04/2012)
4.	Shinagare, Atul B: 15 articles (01/2017 - 11/2012)
5.	Tirumani, Sree Harsha: 12 articles (07/2022 - 05/2013)
6.	Wen, Patrick Y: 12 articles (01/2021 - 02/2003)
7.	Kudo, Masatoshi: 11 articles (09/2019 - 01/2008)
8.	Kondo, Tsunenori: 10 articles (01/2022 - 04/2013)
9.	Takagi, Toshio: 10 articles (01/2022 - 04/2013)
10.	Tanabe, Kazunari: 10 articles (01/2022 - 04/2013)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2021 - "Targeted molecular therapy is the most effective treatment for cancer. " 01/01/2019 - "Molecular targeted therapies with remarkable efficacy are currently in use against various tumors. " 01/01/2022 - "In recent years, molecular targeted therapy and immunotherapy have achieved significant benefits in a variety of tumors. " 12/01/2016 - "The advent of multi-omic profiling of tumors, together with the increasing affordability of high-throughput drug screening programs, has helped usher in a new era of molecular targeted therapies for many solid malignancies. " 05/01/2014 - "Although surgical treatment may be beneficial for tumors without systemic involvement, new chemotherapeutic agents and molecular targeted therapy should be implemented to improve the oncologic outcome in both early and late stage disease."
2.	Renal Cell Carcinoma (Grawitz Tumor) 06/16/2016 - "Molecular targeted therapies have dramatically improved the prognosis of metastatic renal cell carcinoma. " 04/01/2018 - "Molecular targeted therapies have markedly improved the prognosis of metastatic renal cell carcinoma (RCC) and patients are able to receive specific treatments depending on their condition. " 06/01/2012 - "Although molecular targeted therapy has improved the clinical outcome of metastatic renal cell carcinoma, a complete response is rare and there are various side effects. " 09/01/2017 - "Progression-free survival of first-line treatment with molecular-targeted therapy may be a meaningful intermediate endpoint for overall survival in patients with metastatic renal cell carcinoma." 02/01/2017 - "Molecular targeted therapies have improved progression-free survival (PFS) without translating systematically into overall survival (OS) for patients with metastatic renal cell carcinoma (mRCC). "
3.	Melanoma (Melanoma, Malignant) 01/01/2020 - "SLN status is now also being used to identify patients who might benefit from systemic adjuvant therapies such as anti-programmed cell death 1 (PD1) checkpoint inhibitor immunotherapy or BRAF-directed molecular targeted therapy, treatments that have significantly improved relapse-free survival for patients with resected stage III melanoma and improved overall survival of patients with unresectable stage III and stage IV melanoma. " 01/01/2019 - "Although molecular targeted therapies have recently been developed and have improved the overall survival, melanoma patients may show no response and acquisition of resistance to these drugs. " 01/01/2015 - "Recent studies have shown that immunotherapies and molecular targeted therapies are effective for advanced melanoma. " 08/01/2023 - "Further studies are warranted to evaluate the efficacy of systemic immune and targeted molecular therapies, and to identify molecular targets for patients with advanced acral melanoma." 01/01/2021 - "Moreover oncological trials (COMBI-AD, EORTC 1325/KEYNOTE-054 and CheckMate 238) showed that in stage III melanoma patients' chances of recurrence-free survival can be improved by 10-20% by modern immunotherapy and/or molecular targeted therapy. "
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2023 - "Inhibitors targeting specific genetic aberrations present in non-small cell lung cancer (NSCLC), the most common subtype (85%), have improved the prognostic outlook, but due to the complexity of the LC mutational spectrum, only a fraction of patients benefit from these targeted molecular therapies. " 01/01/2020 - "The discovery of oncogenic driver mutations in patients with non-small cell lung cancer over the past 20 years has led to new molecular targeted therapies that have dramatically improved treatment efficacy and quality of life. " 10/06/2022 - "Molecular targeted therapies and immunotherapies for advanced non-small-cell lung cancer have markedly improved outcomes over the past two decades. " 01/01/2022 - "Molecular targeted therapy significantly improved the therapeutic efficacy in non-small cell lung cancer (NSCLC) patients with driver gene mutations but also with new toxicity profiles. " 10/10/2022 - "As we enter an unprecedented era of personalized medicine, molecular targeted therapies have the potential to induce improved survival outcome in patients with non-small cell lung cancer (NSCLC). "
5.	Lung Neoplasms (Lung Cancer) 06/20/2016 - "In recent years, with the advances of techniques in lung cancer diagnosis and the treatment trends towards precision treatment modalities such as individualized therapy and molecular targeted therapy, the survival and prognosis of lung cancer has been significantly improved. " 04/01/2011 - "Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies." 01/01/2016 - "Recently, molecular targeted therapies have shown promising results in the management of lung cancer. " 01/01/2021 - "The development of molecular targeted therapy has improved clinical outcomes in patients with life-threatening advanced lung cancers with driver oncogenes. " 01/01/2022 - "NR2F6 may interact with HNRNPD to jointly regulate the progression of lung cancer, and this conclusion provides a new experimental basis for the study of the molecular targeted therapy of NSCLC."

Related Drugs and Biologics

1.	Tyrosine Kinase Inhibitors
2.	ErbB Receptors (EGF Receptor)
3.	Monoclonal Antibodies
4.	Biomarkers (Surrogate Marker)
5.	Nivolumab
6.	Immune Checkpoint Inhibitors
7.	Anaplastic Lymphoma Kinase
8.	Sorafenib (BAY 43-9006)
9.	Phosphotransferases (Kinase)
10.	Mitogen-Activated Protein Kinase Kinases (MEKs)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Radiotherapy
5.	Molecular Targeted Therapy